Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.88M Buy
96,726
+32,854
+51% +$1.12M ﹤0.01% 4756
2026
Q1
$1.66M Buy
63,872
+33,917
+113% +$1.44M ﹤0.01% 5132
2025
Q4
$1.08M Sell
29,955
-9,593
-24% -$393K ﹤0.01% 5494
2025
Q3
$1.95M Sell
39,548
-10,233
-21% -$415K ﹤0.01% 4973
2025
Q2
$1.57M Sell
49,781
-812
-2% -$18.3K ﹤0.01% 5052
2025
Q1
$910K Buy
+50,593
New +$1.26M ﹤0.01% 5364
2024
Q4
– Sell
-431
Closed -$9.6K – 10160
2024
Q3
$9.6K Buy
+431
New +$7.06K ﹤0.01% 7784
2023
Q2
– Sell
-216
Closed -$1.11K – 9249
2023
Q1
$1.11K Buy
+216
New +$1.26K ﹤0.01% 8810

Other funds holding IPX

UBS Group's IPX Position: Q2 2026 in Review

UBS Group increased its IperionX (IPX) stake by 51% in Q2 2026, buying an estimated $1.12M and bringing the position to 96,726 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #4756.

UBS Group first reported a position in IPX in Q1 2023 and has held it in 8 quarters since. 58 funds tracked by Wall St. Rank hold IPX as of Q2 2026.

  • UBS Group held 96,726 shares of IperionX worth $2.88M as of Q2 2026.
  • UBS Group bought 32,854 IperionX shares in Q2 2026, an estimated $1.12M.
  • IperionX made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4756 holding.
  • UBS Group first reported a position in IperionX in Q1 2023 and has held it in 8 quarters since.
  • 58 funds tracked by Wall St. Rank held IperionX as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.